Glucagon-like peptide-1 (GLP-1) receptor agonist is an injectable drug that can treat type 2 diabetic patients by acting GLP-1 receptors and increasing the secretion of glucose-dependent insulin in contrast to reducing glucagon [65,66]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.